Biotech Values

[mcbio]

McBio thinks that since they didn't test for c-MET in the Phase III, the trial is suspect.

I don't know if "suspect" is the right word. It does raise some questions for the lead indication but I think it was jq that noted before that the Phase 2 results were even more robust because crossover was allowed. So, it's not as if they don't have a chance for success in Phase 3. Still, I may not consider a position until after the initial results are out or, at best, take half a position in front on the initial results. Market cap doesn't exactly look expensive to me at ~$300M market cap, especially when you have other oncology companies like MACK with limited data trading at triple the valuation.